Nucl Med Mol Imaging.
2025 Feb;59(1):94-94. 10.1007/s13139-024-00887-w.
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [ 161Tb]Tb-PSMA and [ 177 Lu]Lu-PSMA in Advanced Prostate Cancer Post [ 177 Lu]Lu-PSMA Failure
- Affiliations
-
- 1Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), 11941 Al-Jubeiha, Amman, Jordan
- 2Department of Medicine, King Hussein Cancer Center (KHCC), 11941 Al-Jubeiha, Amman, Jordan
- 3School of Medicine, University of Jordan, 11942 Al-Jubeiha, Amman, Jordan
- KMID: 2565529
- DOI: http://doi.org/10.1007/s13139-024-00887-w
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177 Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
- Preparation of Patient Doses of [177Lu]Lu‑DOTATATE and [177Lu] Lu‑PSMA‑617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
- 161Tb‑PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer
- The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
- Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617
